Eli Lilly, Insulin Makers Sued by California Over Prices
- Three drug companies produce 90% of insulin, Bonta says
- High drug prices disproportinately affect people of color
Boxes of Eli Lilly & Co. insulin medication.
Photographer: Daniel Acker/BloombergThis article is for subscribers only.
Eli Lilly & Co., Novo Nordisk AS and Sanofi were sued by California over insulin prices, which the state claims are inflated through unfair and deceptive practices and disproportionately affect low-income households and people of color.
The suit filed Thursday also claims pharmacy benefit managers CVS Caremark, Express Scripts, and OptumRx as well as the drug makers “have leveraged their market power to overcharge patients,” according to a statement from Attorney General Rob Bonta’s office.